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Abstract
Background: Substantial evidence suggests that consuming 1–2 servings of fish per week, particularly oily fish
(e.g., salmon, herring, sardines) is beneficial for cardiovascular health due to its high n-3 polyunsaturated fatty acid
content. However, there is some concern that the mercury content in fish may increase cardiovascular disease risk,
but this relationship remains unclear.
Methods: The PREDIMED trial included 7477 participants who were at high risk for cardiovascular disease at
baseline. In this study, we evaluated associations between mercury exposure, fish consumption and cardiovascular
disease. We randomly selected 147 of the 288 cases diagnosed with cardiovascular disease during follow-up and
matched them on age and sex to 267 controls. Instrumental neutron activation analysis was used to assess toenail
mercury concentration. In-person interviews, medical record reviews and validated questionnaires were used to
assess fish consumption and other covariates. Information was collected at baseline and updated yearly during
follow-up. We used conditional logistic regression to evaluate associations in the total nested case-control study,
and unconditional logistic regression for population subsets.
Results: Mean (±SD) toenail mercury concentrations (μg per gram) did not significantly differ between cases
(0.63 (±0.53)) and controls (0.67 (±0.49)). Mercury concentration was not associated with cardiovascular disease in
any analysis, and neither was fish consumption or n-3 fatty acids. The fully-adjusted relative risks for the highest
versus lowest quartile of mercury concentration were 0.71 (95% Confidence Interval [CI], 0.34, 1.14; ptrend = 0.37)
for the nested case-control study, 0.74 (95% CI, 0.32, 1.76; ptrend = 0.43) within the Mediterranean diet intervention
group, and 0.50 (95% CI, 0.13, 1.96; ptrend = 0.41) within the control arm of the trial. Associations remained null
when mercury was jointly assessed with fish consumption at baseline and during follow-up. Results were similar
in different sensitivity analyses.
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Conclusions: We found no evidence that mercury exposure from regular fish consumption increases cardiovascular
disease risk in a population of Spanish adults with high cardiovascular disease risk and high fish consumption. This
implies that the mercury content in fish does not detract from the already established cardiovascular benefits of fish
consumption.
Trial registration: ISRCTN35739639.
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Background
Overwhelming evidence demonstrates that even modest
fish consumption (1–2 servings per week) has extensive
health benefits, particularly for cardiovascular health. A
recent systematic review reported that this relatively low
level of fish consumption was associated with a 36% de-
creased risk of fatal coronary heart disease (CHD) and a
17% decreased risk of total mortality compared to <1
serving/week of fish consumption. Health benefits of
modest but regular fish consumption occur within only
months, but greater benefits occur with longer duration
of intake. Oily fish (e.g., salmon, herring, sardines) may
be especially beneficial, as they are relatively higher in
two long-chain n-3 polyunsaturated fatty acids (n-3
PUFAs), eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA). EPA and DHA have been identified as
the active constituents for cardiovascular benefits [1].
Furthermore, in many western societies it is likely that
fish consumption displaces and thus reduces consump-
tion of red and processed meat, and this reduction is as-
sociated with many health benefits [2–10].
Despite these health benefits of fish intake, there is
concern about the potential adverse effects of mercury
from fish; fish is a major source of mercury [11], which,
at extremely high levels, has been shown to result in ser-
ious health complications including cardiovascular dis-
ease [1]. Several studies investigating the relationship
between fish intake, mercury exposure and cardiovascu-
lar disease in adults have generated inconsistent results
[12–19]. As a result, government agencies and health
organizations have identified mercury exposure from
fish consumption as an area needing further investiga-
tion [1, 20–23]. The present study seeks to clarify
whether current Mediterranean diet recommendations
of fish consumption (1–2 servings of fish per week),
elevate mercury exposure to levels that increase risk of
cardiovascular disease.
Extensive evidence supports that toenail concentration
of methylmercury is an excellent biomarker for long-
term mercury exposure [24–29]. A nested case-control
study in the United States of 3427 cardiovascular disease
cases and 3427 matched controls assessed mercury ex-
posure by measuring toenail mercury concentration.
They found no adverse effects of mercury exposure on
coronary heart disease, stroke or total cardiovascular dis-
ease [11]. Another analysis using the same data found
no adverse effects of mercury exposure on hypertension.
This was true for levels 2.5-fold higher than the U.S.
Environmental Protection Agency reference dose [30].
A 2012 review of mercury exposure and human health
concluded that there is no clear relationship between
mercury exposure and cardiovascular disease [31]. Thus,
further evidence is needed before altering any policies or
recommendations regarding mercury exposure through
fish intake. We prospectively analyzed the associations
between mercury exposure through fish intake and car-
diovascular disease in PREDIMED, a large clinical trial
of nutritional intervention for the primary prevention of
cardiovascular disease. Our study population has unique
characteristics for studying this association because our
participants are at high risk of cardiovascular disease
and they tend to consume large amounts of fish, and
thus likely have higher levels of mercury exposure
through fish consumption; per capita fish consumption
in Spain is approximately twice the average of European
countries [32], and fish consumption was even higher
among PREDIMED participants randomized to the
Mediterranean Diet.
Methods
Study design
The design and methods of the PREDIMED trial have
been described previously [33, 34]. The PREDIMED trial
was a randomized, controlled, cardiovascular disease
prevention trial based in 11 centers throughout Spain
[35]. Institutional Review Boards at all participating cen-
ters approved the study protocol.
Eligible participants included men (55–80 year) and
women (60–80 year) at high risk for developing cardio-
vascular disease at enrollment, but had never been diag-
nosed with cardiovascular disease. High risk was defined
as having type 2 diabetes mellitus or at least three of the
following major risk factors: current smoking, hyperten-
sion, elevated low-density lipoprotein cholesterol levels,
overweight or obesity or a familial history of premature
coronary heart disease. 7447 participants were recruited
between 2003 and 2009. After providing written informed
consent, they were randomized to either a traditional
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Mediterranean diet supplemented with either extra virgin
olive oil or tree nuts, or a control (low-fat) diet. The
primary cardiovascular disease endpoint was defined as
non-fatal acute myocardial infarction, non-fatal stroke or
cardiovascular death. Hojiblanca and Patrimonio Commu-
nal Olivarero donated extra-virgin olive oil; the California
Walnut Commission donated walnuts; Borges donated al-
monds; La Morella Nuts donated hazelnuts. Sponsors
played no role in the design, analysis, interpretation or
manuscript writing.
To evaluate the association between fish consumption,
mercury exposure and cardiovascular disease, we de-
signed a nested case-control study within the framework
of the PREDIMED trial.
Cases and controls
7,232 (97.1%) of PREDIMED participants provided toenail
clippings at baseline, within 6 months of randomization.
Among the PREDIMED participants who provided toenail
samples, we randomly selected 147 of the 288 cases of in-
cident cardiovascular disease (according to the definition
of the primary end-point of the trial) during subsequent
follow-up. The median follow-up period from time of toe-
nail sampling to time of incident cardiovascular disease
was 4.8 years (interquartile range 3.0–5.8 years). Out-
comes were identified through repeated contacts with par-
ticipants, contacts with family physicians, annual medical
record review and consultation of the National Death
Index. The End-Point Adjudication Committee was
blinded to the randomized intervention group and every
exposure, and ascertained outcomes. Only confirmed out-
comes (non-fatal acute myocardial infarction, non-fatal
stroke and cardiovascular death) were included as a case.
Cases were randomly matched on age (within 2 years) and
sex to 267 controls who were free from cardiovascular
disease before December 2010 and had provided toenail
samples at baseline. Most cases were matched to two con-
trols, but 23 cases were matched to only one control.
Measurement of exposure
The concentration of total methylmercury in the stored
toenails was assessed using instrumental neutron activa-
tion analysis (INAA) at the Interfaculty Reactor Institute
at Delft University of Technology in Delft, Netherlands.
Supplemental materials provide details of analytic
methods and validation of these methods [36].
Specifics of the dietary intervention are provided in
detail elsewhere [37]. Registered dietitians conducted
one-on-one in-person interviews to collect participants’
dietary information at baseline. We administered a vali-
dated 137-item food frequency questionnaire (FFQ) at
baseline and yearly thereafter during the follow-up [38].
Participants reported how often, on average over the last
year, they consumed each food item (never or almost
never, 1–3 times per month, 1 time per week, 2–4 times
per week, 5–6 times per week, 1 time per day, 2–3 times
per day, 4–6 times per day and >6 times per day). Fish
items include white fish (grouper, flounder, sea bream,
hake, whiting; 1 serving), dark-meat fish (sardines, tuna,
bonito, mackerel, salmon; 1 serving or 130 g); salted fish
(cod or salted fish product; 1 serving or 60 g); oysters,
clams, mussels (6 units); squid, octopus, cuttlefish (1 serv-
ing or 200 g); shellfish (shrimp, prawns, crayfish, etc.; 4–5
pieces or 200 g); natural canned seafood (sardines, ancho-
vies, bonito, tuna; 1 small can or half normal can or 50 g);
seafood in oil (sardines, anchovies, bonito, tuna; 1 small
can or half normal can or 50 g). We used this information
to calculate average fish consumption (in grams per day).
Covariate assessment
Covariates were measured at baseline and yearly over
follow-up. We reviewed medical records and used stan-
dardized validated protocols [39] to collect information on
sociodemographic, lifestyle, health, family history and
medical diagnoses. A validated Spanish version of the
Minnesota Leisure Time Physical Activity Questionnaire
[40] was used to evaluate physical activity. Trained nurses
measured weight and height using standardized proce-
dures, and blood pressure using a validated semiautomatic
oscillometer in triplicate (Omron HEM_705CP). Yearly
glucose tests identified new cases of diabetes. We de-
veloped and validated a 14-item Mediterranean diet ad-
herence tool [41] to repeatedly assess adherence at
baseline and during the intervention period. We used
the validated FFQ described above to calculate total al-
cohol and energy intake. Primary care doctors assessed
participants for hypercholestaerolemia, hypertension
and type 2 diabetes diagnoses.
Statistical analysis
To examine the association of toenail mercury concentra-
tion with cardiovascular disease in the nested case-control
study’s total population, we used multivariate-adjusted
conditional logistic regression, matching on age and sex.
For separate analyses of the intervention groups or control
group, we used multivariate-adjusted unconditional lo-
gistic regression, adjusting for matching factors. Mercury
concentrations (μg/g) were categorized into quartiles
based on the distribution among controls. To test for
trend, we used the median value of the appropriate quar-
tile of mercury and treated it as a continuous variable.
We again used multivariate-adjusted conditional logistic
regression to evaluate mercury exposure in conjunction
with fish consumption in the total nested case-control
study. Baseline fish consumption was dichotomized into
low and high groups according to the PREDIMED 14-
item Mediterranean diet adherence tool (high: ≥3
servings/week) [41]. Mercury exposure was dichotomized
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as above or below the median value. We then created four
exposure categories (low mercury/low fish, low mercury/
high fish, high mercury/low fish, high mercury/high fish),
which we included as indicator variables. The same condi-
tional logistic regression methods were used to evaluate
mercury exposure and increase in fish consumption in the
nested case-control study. We cross-classified increase in
fish consumption from baseline to three years of follow-
up (increased or not increased) with baseline toenail mer-
cury concentration (above or below median).
We also used multivariate-adjusted unconditional lo-
gistic regression to perform the following sensitivity ana-
lyses: 1) excluding diagnosed with cardiovascular disease
within one year of baseline; 2) excluding those diagnosed
over five years after toenail collection (baseline); 3) ex-
cluding participants above the 90th percentile of toenail
selenium concentration; 4) stratifying on baseline fish in-
take (high/low), 5) restricting to participants at very high
risk of cardiovascular disease (>70 years old with dia-
betes and hypertension at baseline); and 6) stratifying on
baseline aspirin use (yes/no).
To control for potential confounders, we included in
all models those variables based on clinical relevance
and previous causal knowledge, as listed in the table
footnotes. To evaluate the associations of fish and intake
and mercury levels across the distribution of mercury
exposure, we constructed restricted cubic splines.
All p-values are two-tailed. Values less than 0.05 are
considered statistically significant. We performed all
statistical analyses using Stata 12.0.
Results
Study population
Table 1 shows baseline characteristics for cases and con-
trols. The mean (±SD) age was 69 years, and approxi-
mately 41% of the population was female. There was no
significant difference in toenail mercury levels between
cases and controls: the mean (±SD) level was 0.63
(±0.53) μg per gram for cases and 0.67 (±0.49) μg per
gram for controls. Although they are measured on differ-
ent scales, toenail mercury levels represent a well-
established mercury biomarker which is closely correlated
with blood levels (r = 0.78). For reference, 1 μg per gram
of toenail mercury concentration corresponds to approxi-
mately 20 μg per liter of blood mercury concentration
[42]. Levels of fish and seafood consumption, n-3 fatty
acids and all other relevant dietary factors were similar.
Statistically significant differences were observed only for
history of type 2 diabetes (higher among cases) and Medi-
terranean diet adherence (higher among controls). This
difference was expected, as both history of type 2 diabetes
and poor adherence to the Mediterranean diet are risk fac-
tors for cardiovascular disease [43, 44].
Mercury exposure and risk of cardiovascular disease
The fully-adjusted relative risk (RR) for the highest ver-
sus lowest quartile of toenail mercury (Table 2) was 0.71
(95% Confidence Interval [CI], 0.34, 1.14; ptrend = 0.37)
for the nested case-control study. When we stratified by
the three randomized arms of the PREDIMED trial, the
RRs were 0.74 (95% CI, 0.32, 1.76; ptrend = 0.43) within
the Mediterranean diet intervention groups, and 0.50
(95% CI, 0.13, 1.96; ptrend = 0.41) within the control arm
of the trial.
Higher toenail mercury concentration was not associ-
ated with increased cardiovascular disease risk in our
nested case-control study. After adjusting for age, sex,
month of toenail collection, PREDIMED center, smok-
ing, hypertension, hypercholestaerolemia, diabetes and
family history of premature CHD, we found no associ-
ation (OR, 0.56; 95% CI, 0.28, 1.12; ptrend = 0.09), as did
results after further adjusting for intervention group,
baseline adherence to Mediterranean diet, body mass
index (BMI), physical activity, alcohol intake, fish intake
and n-3 fatty acid intake from sources other than fish
(OR, 0.66; 95% CI, 0.31, 1.41; ptrend = 0.11) (Table 2).
When we separately analyzed the Mediterranean diet
intervention groups and control (low-fat) group, we con-
tinued to observe no increase in cardiovascular disease
risk for the comparison between extreme quartiles of
mercury exposure in unconditional logistic regression
models adjusted for age, sex and PREDIMED center
(Mediterranean diet arm: OR, 0.72; 95% CI, 0.33, 1.55;
p = 0.32; Control arm: OR, 0.40; 95% CI, 0.12, 1.34;
ptrend = 0.13), or fully-adjusted unconditional logistic re-
gression models (Mediterranean diet: OR, 0.74; 95% CI,
0.31, 1.75; ptrend = 0.67; Control: OR, 0.63; 95% CI, 0.15,
2.61; ptrend = 0.75) (Table 2).
Mercury exposure, fish consumption and risk of
cardiovascular disease
Table 3 compares risk of cardiovascular disease among
those with different baseline levels of both fish intake
and mercury levels. Compared to those with both low
mercury concentration and low fish consumption at
baseline, we observed no significant associations with
cardiovascular disease for any of the three other groups.
Results remained null after adjusting for month of toe-
nail collection, PREDIMED center, age, smoking, hyper-
tension, hypercholestaerolemia, diabetes and family
history of premature CHD, and after additionally adjust-
ing for intervention group, total energy intake, BMI,
physical activity, alcohol intake and n-3 fatty acid intake
from non-fish sources. The point estimates in the dose-
response trend suggested an initial reduction in risk with
higher levels of toenail mercury that plateaued thereafter
with even higher mercury levels (Fig. 1). However, the
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confidence intervals were compatible the null value
across all mercury levels.
Compared to those with low mercury concentration
and no increase in fish consumption from baseline to
the third year of follow-up, increased fish consumption
was not significantly associated with cardiovascular dis-
ease risk. Results remained null in the multivariable ad-
justed models. The fully-adjusted OR for the highest
mercury concentration and no increase in fish consump-
tion was 0.54; 95%CI, 0.20–1.44) (Table 4).
Sensitivity analyses
All sensitivity analyses of various subsets of our nested
case-control study produced similar non-significant re-
sults. We observed no association after excluding cases
diagnosed within one year or over five years of baseline,
excluding participants with high toenail selenium levels,
stratifying on baseline fish intake, restricting to partici-
pants at very high risk of cardiovascular disease, and
stratifying on baseline aspirin use (Additional file 1:
Tables S1–S6).
Table 1 Baseline characteristics of case participants with incident cardiovascular disease and of controls in the PREDIMED
Characteristic Case participants Control participants p value
n 147 271
Age 69.2 (6.4) 68.6 (6.1) Matching Factor
Female sex (%) 40.3 40.5 Matching Factor
PREDIMED trial arm (%) 0.03
Mediterranean diet + EVOO 37.4 37.6
Mediterranean diet + nuts 24.5 35.1
Smoking status (%) 0.39
Current smoker 19.7 15.1
Former smoker 34.0 32.8
Hypercholesterolaemia (%) 57.1 65.3 0.10
Hypertension (%) 80.3 77.5 0.51
Type 2 diabetes (%) 61.2 49.1 0.02
Family history of CHD (%) 19.7 15.5 0.27
Body mass index (kg/m2) 29.7 (3.6) 29.7 (3.5) 0.94
Physical activity (METs-min/d) 250.2 (211.1) 279.0 (272.5) 0.27
Alcohol (g/d) 10.1 (16.8) 12.7 (17.9) 0.15
Toenail mercury (μg/g) 0.63 (0.53) 0.67 (0.49) 0.42
Dietary intake
Fish and seafood (g/d) 92.4 (46.0) 93.5 (44.1) 0.80
n-3 Fatty acids (EPA & DHA) (g/d) 0.71 (0.46) 0.75 (0.44) 0.34
n-3 Fatty acids (other) 1.41 (0.65) 1.44 (0.65) 0.72
Total energy intake (kcal/d) 2340 (645) 2363 (599) 0.71
Total Fat (%E) 39.5 (6.5) 39.7 (6.6) 0.70
Monounsaturated Fat (%E) 19.6 (4.4) 20.0 (4.6) 0.47
Polyunsaturated Fat (%E) 6.2 (2.2) 6.2 (1.8) 0.92
Saturated Fat (%E) 10.4 (2.3) 10.1 (2.2) 0.29
Protein (%E) 16.2 (2.9) 15.8 (2.7) 0.16
Cholesterol (mg/d) 363.0 (122.2) 366.5 (130.9) 0.78
Fiber (g/d) 24.9 (10.3) 25.1 (7.9) 0.78
Mediterranean diet adherence (0–14) 8.2 (2.0) 8.8 (1.8) 0.001
Fish item in Mediterranean screener (%) 52.1 51.7 0.94
Means (standard deviations) unless otherwise stated
EVOO extra-virgin olive oil, CHD coronary heart disease, METs metabolic equivalents, EPA eicosapentanoic acid, DHA docosahexanoic acid, %E percent of total
energy intake, OR odds ratio, CI confidence Interval, Hg mercury
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Discussion
Our results indicate that mercury exposure, as assessed
by an objective biomarker, was not associated with in-
creased cardiovascular disease among Spanish adults age
55–80 years despite their being at high risk for cardiovas-
cular disease and having relatively high fish consumption.
There was no significant association in the total popula-
tion sample used for our nested case-control study, among
the subset randomized to the Mediterranean diet, or
among the subset randomized to the control (low-fat)
group. There was also no association between toenail
mercury levels and cardiovascular disease in our total
Table 2 Relative risk of cardiovascular disease, according to quartiles of toenail mercury, among case participants and matched
controls in the PREDIMED trial
Variable Sex-specific quartiles of toenail mercury
number of cases Q1 Q2 Q3 Q4 p for trend
Mean mercury (μg/g) 0.25 (0.08) 0.43 (0.05) 0.65 (0.10) 1.30 (0.62)
Total samplea
Cases/matched controls 147/267 44/60 39/66 33/72 31/69
Matched OR (95% CI) 1 (ref.) 0.93 (0.51, 1.70) 0.76 (0.42, 1.39) 0.60 (0.32, 1.13) 0.09
Matched ORb (95% CI) 1 (ref.) 0.91 (0.48, 1.71) 0.84 (0.44, 1.59) 0.56 (0.28, 1.12) 0.09
Matched ORc (95% CI) 1 (ref.) 0.86 (0.43, 1.72) 0.85 (0.43, 1.72) 0.66 (0.31, 1.41) 0.11
Mediterranean diet interventiond
Cases/controls 91/197 23/39 25/49 20/55 23/54
Adjusted OR (95% CI) 1 (ref.) 0.99 (0.46–2.12) 0.66 (0.30, 1.46) 0.72 (0.33, 1.55) 0.32
Adjusted ORe (95% CI) 1 (ref.) 0.96 (0.43–2.14) 0.71 (0.30, 1.64) 0.66 (0.29–1.49) 0.27
Adjusted ORf (95% CI) 1 (ref.) 1.00 (0.43, 2.32) 0.68 (0.28, 1.63) 0.74 (0.31, 1.75) 0.67
Control (low-fat) groupd
Cases/controls 56/74 21/22 14/17 13/18 8/18
Adjusted OR (95% CI) 1 (ref.) 0.97 (0.35, 2.64) 0.78 (0.28, 2.17) 0.40 (0.12, 1.34) 0.13
Adjusted ORe (95% CI) 1 (ref.) 1.08 (0.36, 3.23) 0.99 (0.33, 2.98) 0.44 (0.12, 1.64) 0.25
Adjusted ORf (95% CI) 1 (ref.) 1.11 (0.34, 3.64) 1.06 (0.34, 3.38) 0.63 (0.15, 2.61) 0.75
aModels are from conditional logistic regression analyses with matching factors sex and age and adjusted for PREDIMED center
bAdditionally adjusted for age, month of toenail collection, smoking, hypertension, hypercholestaerolemia, diabetes and family history of premature coronary
heart disease
cAdditionally adjusted for intervention group, baseline adherence to the Mediterranean diet, body mass index, physical activity (quartiles), alcohol intake
(<5/10 gr, moderate consumption, >25/50 g in women/men), fish intake (continuous g/d) and non-fish consumption of n-3 fatty acids (continuous g/d)
dModels are from multivariate-adjusted logistic regression, adjusted for sex, age and PREDIMED center
eAdditionally adjusted for month of toenail collection, smoking, hypertension, hypercholestaerolemia, diabetes and family history of premature coronary
heart disease
fAdditionally adjusted for intervention group, baseline adherence to the Mediterranean diet, body mass index, physical activity (quartiles), alcohol intake
(<5/10 gr, moderate consumption, >25/50 g in women/men), fish intake (continuous g/d) and non-fish consumption of n-3 fatty acids (continuous g/d)
Table 3 Relative risk of cardiovascular disease, according to baseline toenail mercury and fish/seafood consumption, among case
participants and matched controls in the PREDIMED trial
Baseline toenail Mercury and fish/seafood consumption
Low Hg/Low Fish Low Hg/High Fish High Hg/Low Fish High/High
Mean mercury (μg/g) 0.31 (0.12) 0.36 (0.09) 0.92 (0.52) 0.99 (0.56)
Fish/seafood consumption (g/d) 62 (39) 119 (39.4) 75 (36) 115 (35)
Total sample
Cases/matched controls 41/73 37/52 29/58 39/88
Matched ORa (95% CI) 1 (ref.) 1.09 (0.56, 2.11) 0.66 (0.33, 1.31) 0.85 (0.48, 1.50)
Matched ORb (95% CI) 1 (ref.) 1.08 (0.53, 2.19) 0.68 (0.32, 1.44) 0.85 (0.46, 1.55)
Matched ORc (95% CI) 1 (ref.) 1.18 (0.51, 2.77) 0.73 (0.34, 1.59) 0.91 (0.43, 1.93)
aModels are from conditional logistic regression analyses with matching factors sex and age and adjusted for PREDIMED center
bAdditionally adjusted for month of toenail collection, smoking, hypertension, hypercholestaerolemia, diabetes and family history of premature coronary
heart disease
cAdditionally adjusted for intervention group, total energy intake, body mass index, physical activity (quartiles), alcohol intake (<5/10 gr, consumption, >25/50 g in
women/men) and non-fish consumption of n-3 fatty acids (continuous g/d)
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population sample when we analyzed mercury exposure
in conjunction with baseline fish intake or change in fish
intake between baseline and one year of follow-up.
Null results from all sensitivity analyses demonstrate
that our findings are robust. Lack of association after ex-
cluding those diagnosed with cardiovascular disease
more than five years after toenail collection showed that
potential misclassification of exposure due to variation
over time did not attenuate results. We found no associ-
ation after excluding participants with high toenail
selenium levels, suggesting that the potentially protect-
ive effect of selenium against mercury toxicity did not
influence our associations. Similarly, we found no asso-
ciations after stratifying on low versus high fish intake
or adjusting for fish intake, further supporting that our
lack of association between mercury exposure and
cardiovascular disease risk was not attributable to the
potentially protective effect of fish consumption. The
lack of association after restricting to participants at
very high risk of cardiovascular disease suggests that
these levels of mercury exposure from moderate fish
consumption probably do not represent reason for
concern regarding cardiovascular risk even for the
highest-risk, most susceptible individuals. We found no
association after stratifying on baseline aspirin use (yes/
no), suggesting that the potentially protective effect of
aspirin on cardiovascular disease [45] also does not in-
fluence this relationship.
Many previous studies have investigated the relation-
ship between mercury exposure and cardiovascular
disease [11–18, 30]. The majority of findings are null,
consistent with our own results. The few studies that
Fig. 1 Restricted cubic spline analysis for the dose-response trend between toenail mercury levels and risk of cardiovascular disease (Odds Ratios,
95% confidence intervals from a fully-adjusted multivariable conditional logistic regression model)
Table 4 Relative risk of cardiovascular disease, according to increases in fish/seafood consumption from baseline to third year of
follow-up and baseline toenail mercury, among case participants and matched controls in the PREDIMED trial
Increase in Fish/seafood consumption & baseline toenail Mercury
Low Hg/No increase in fish Low Hg/Increased Fish High Hg/No increase in fish High Hg/Increased Fish
Mean mercury (μg/g) 0.33 (0.11) 0.33 (0.10) 0.99 (0.59) 0.84 (0.26)
% with high fish in MeDiet score 52 100 67 100
Total sample
Cases/matched controls 62/87 16/38 54/116 14/30
Matched ORa (95% CI) 1 (ref.) 0.46 (0.21, 1.01) 0.62 (0.38, 1.03) 0.48 (0.20, 1.15)
Matched ORb (95% CI) 1 (ref.) 0.52 (0.23, 1.17) 0.65 (0.38, 1.12) 0.52 (0.20–1.34)
Matched ORc (95% CI) 1 (ref.) 0.50 (0.21, 1.18) 0.66 (0.37, 1.16) 0.54 (0.20, 1.44)
aModels are from conditional logistic regression analyses with matching factors sex and age and adjusted for PREDIMED center
bAdditionally djusted for month of toenail collection, smoking, hypertension, hypercholestaerolemia, diabetes and family history of premature coronary
heart disease
cAdditionally adjusted for intervention group, total energy intake, body mass index, physical activity (quartiles), alcohol intake (<5/10 gr, moderate consumption,
>25/50 g in women/men) and non-fish consumption of n-3 fatty acids (continuous g/d)
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observed positive associations had critical limitations
[12, 13, 18, 19]. One case-control study that found a
positive association with nonfatal myocardial infarction
was retrospective and had higher rates of participation
among cases. Thus, selection and recall bias may have
affected their results [12]. A prospective study found a
positive association with incident coronary disease, but
with no dose-response relationship, and no association
with overall cardiovascular mortality [13]. Two cross-
sectional studies found positive associations – one with
cardiovascular disease [18], and another with arterial
stiffness [19]. Yet cross-sectional designs cannot estab-
lish causality, and both of these studies measured blood
rather than toenail mercury concentration. Blood sam-
ples are not as well time-integrated as nail samples; red
blood cells typically have a 17-week turnover, compared
to 26–52 weeks for toenails [46]. However, these limita-
tions do not entirely discount their credibility; policy
and dietary recommendations regarding fish intake, mer-
cury exposure and cardiovascular disease should be
made in light of the entire body of evidence and should
also take into account other non-cardiovascular harmful
effects of mercury toxicity.
Our findings should not impact policies surrounding
mercury pollution. The relationship between very high
mercury exposure and increased risk of many health
complications has been consistently demonstrated in
other studies. The main application of our findings
should be dietary recommendations for moderate to
high fish consumption as part of ideal diets for cardio-
vascular disease prevention.
However, our findings do suggest that existing concerns
for potential cardiovascular risk surrounding mercury ex-
posure from fish consumption are probably unwarranted.
Several aspects of our study population make these null
results particularly meaningful. First, all participants are
already at high risk of cardiovascular disease. Thus, any
increased risk from mercury would be very likely to cause
cardiovascular disease events. Second, our participants
consume very high levels of fish. Per capita seafood con-
sumption in Spain is approximately twice the average for
European countries [32]. The intervention group is en-
couraged to consume even more fish than what is typical
in Spain. The mean fish intake in our study population is
approximately 92.7 g/day, compared to approximately
31.6 g/day [11], 43 g/day [13], 30.4 g/day [14], and 39.3 g/
day [19] in previous studies. The observed lack of in-
creased cardiovascular risk in this population provides
evidence that consuming even the highest levels of fish
consumption do not increase mercury exposure to dan-
gerous levels. The observed null findings in this popula-
tion provide evidence that mercury exposure from
relatively high fish consumption (e.g. 3 servings/week) is
unlikely to increase risk of cardiovascular disease. Third,
our population has much higher levels of mercury (0.66
μg/g) compared to three out of four of the populations
that observed a positive association between mercury
exposure and cardiovascular disease (0.26 μg/g [12], 0.45
μg/g [18], and 0.30 μg/g [19]). This suggests that higher
mercury exposure is not associated with increased risk of
cardiovascular disease in the context of a healthy Mediter-
ranean diet with high fish intake.
These null results are likely generalizable to popula-
tions with lower cardiovascular disease risk and lower
fish consumption, since any harmful effects of mercury
exposure would have even less impact among these
people. Toenail mercury concentration is an objective,
stable and time-integrated biomarker. Our prospective
study design and our exposure assessment using an ob-
jective biomarker prevents recall bias.
In a recent report we showed the benefits of long-chain
w-3 fatty acids from fish in the total data base of the
trial.47 The hazard ratios for intake of corresponding to
the levels of long-chain n-3 polyunsaturated fatty acids
recommended by the International Society for the Study
of Fatty Acids and Lipids were 0.84 (95% CI 0.67–1.05) for
all-cause mortality, 0.61 (95% CI 0.39–0.96) for fatal car-
diovascular disease, 0.54 (95% CI 0.29–0.99) for fatal cor-
onary heart disease, and 0.49 (95% CI 0.22–1.01) for
sudden cardiac death. In addition, there is extensive avail-
able evidence supporting the cardiovascular benefits of
fish consumption discussed above. However, it should not
be surprising that in the participants included in this sub-
study we didn’t find associations between fish intake and
cardiovascular disease. Virtually all established dietary
guidelines recommend at least 1–2 servings of fish per
week (1 serving = approximately 75 g) for cardiovascular
benefits. Furthermore, evidence suggests that higher levels
of fish intake does not confer added benefits.1 Our study
population consumes an average of 95 g of fish per day. It
is likely that we have too small a sample size and an insuf-
ficient range of exposure (i.e. average fish consumption is
too high) to observe the cardiovascular benefits of fish
consumption within this case-control substudy of mercury
exposure.
There are limitations to our study that warrant contin-
ued investigation of this issue. We only have one meas-
ure of toenail mercury concentration, but toenail
mercury concentrations have high reproducibility over
time and low within-person to between-person variation
ratio. This suggests that our single measure is a strong
indicator of long-term intake [26]. However, true associ-
ations may still be attenuated. For example, it is possible
that measurement error contributed to our null results.
We did not have biological measurements for n-3 fatty
acids. Although the FFQ has been validated in this
population, fish vary in their n-3 fatty acid content [47],
and the FFQ is still an imprecise measurement of n-3
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fatty acids. Thus it is possible that imprecise measure-
ment might have created residual negative confounding,
as n-3 fatty acids would likely be positively associated
with fish intake, and thus mercury levels, but inversely
associated with cardiovascular disease. To address this,
we conducted a bias analysis to assess the degree of
plausible bias due to residual confounding by n-3 fatty
acid intake (dichotomized at the median) based on our
observed OR of 0.66 in Table 2, comparing the highest
to lowest quartile of toenail mercury (Additional file 1:
Table S7). We found that the odds ratio for the associ-
ation between a dichotomous confounder (n-3 fatty acid)
and cardiovascular disease would need to be as low as
0.2, and difference in prevalence of the confounder (high
n-3 fatty acid intake in the exposed (highest quartile of
mercury intake) compared to unexposed (lowest quartile
of mercury intake) must be very extreme (e.g. 0.2 in ex-
posed, 0.8 in unexposed) to render the association as
detrimental. Acknowledging that toenail mercury con-
centration is also a biomarker for fish intake, and fish in-
take is associated with reduced cardiovascular disease
risk, there could be negative residual confounding by
fish intake or n-3 PUFA intake. This previously observed
inverse association between fish intake and cardiovascu-
lar disease was not apparent in our data, probably be-
cause even in the lowest categories of fish consumption
in our participants, the amount of fish consumed was
already sufficiently high. While we believe it is unlikely
that fish intake may strongly confound our results, be-
cause we already adjusted for fish intake, we acknow-
ledge that residual confounding may yet exist and that
our bias analysis results are subject to different interpre-
tations. Based on previous evidence, we believe that it is
unlikely, that the cardiovascular benefits of n-3 PUFAs
are strong enough to account for a residual confounding
of such magnitude as to explain the lack of association
observed between mercury levels and cardiovascular
disease. High n-3 PUFA consumption would need to be
associated with approximately 0.11 the odds of cardio-
vascular disease compared to low n-3 PUFA consump-
tion assuming a high association (OR = 5) between
mercury and n-3 intake (Additional file 1: Table S7). A
2011 review included summarized 15 different meta-
analysis RCTs and prospective cohort studies analyzing n3
PUFAs and various cardiovascular disease outcomes, in-
cluding cardiovascular death, coronary heart disease,
stroke and others. The lowest RR of these 15 meta-
analyses was 0.62 (0.46–0.82) [48]. Despite this, we still
manipulated the prevalence of the confounder to be 0.11
and higher (0.23, 0.43, 0.62, 0.81). Even at a confounder-
disease OR of 0.43, which is likely still too low given that
the higher RRs from the extensive meta-analyses [48], the
corrected RR would be 0.90. Under the 0.23 confounder-
disease OR, almost certainly too extreme, it would be 1.13.
While we believe that these results indicate that residual
confounding from n-3 PUFA is probably insufficient to ex-
plain our results, we admit that this interpretation may be
subjective and that under some of the scenarios shown in
Additional file 1: Table S7, the association mercury-CVD
could be detrimental.
To minimize participant burden, our FFQ did not ask
about consumption of specific types of fish. Thus, we
could not obtain direct measurements of association be-
tween type of fish intake and toenail mercury concentra-
tions. Seafood varies in mercury content [49], although
mercury content of popular Spanish seafood have rela-
tively consistent mercury levels [50]. Lastly, our sample
size is small and many models are adjusted for many co-
variates, thus limiting our power, particularly when we
adjust rather than match for sex and age in uncondi-
tional logistic regression models. However, it has been
empirically demonstrated that the the rule of thumb
usually suggested (adjusting for one confounder for
every 10 events) can be relaxed [51]. However, the
unique characteristics of our population described
above, and the inverse association suggested by our
point estimates, make it unlikely that we would have
missed a material positive association between mercury
exposure and cardiovascular disease. The role of other
heavy metals in cardiovascular disease in this population
merits further studies.
Conclusion
Mercury exposure from fish intake did not appear to in-
crease cardiovascular disease risk in our sample of high
risk participants exposed to high levels of fish consump-
tion and consequently mercury concentrations, though
under some assumptions on residual confounding by n-
3 fatty acids, a slightly increased risk could persist. We
did not observe any substantial risk in this unique set-
ting of elderly participants with high cardiovascular dis-
ease risk, high fish intake and relatively high toenail
mercury concentrations. These findings have important
public health implications, as they suggest that the mer-
cury content in fish is not very likely to discount the
well-known cardiovascular benefits of fish consumption.
Based on our findings, dietary recommendations should
continue to include high fish intake as part of a healthy
diet. Our findings, coupled with previous extensive evi-
dence, support the dietary recommendation of at least
1–2 servings of fish per week for the prevention of car-
diovascular disease.
Additional file
Additional file 1: Table S1. Relative Risk of Cardiovascular Disease,
according to quartiles of toenail mercury, among case participants and
matched controls in the PREDIMED trial, restricted to those who were
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not diagnosed with cardiovascular disease within one year of follow-up.
Table S2. Relative Risk of Cardiovascular Disease, according to quartiles
of toenail mercury, among case participants and matched controls in the
PREDIMED trial, restricted to those who were diagnosed with cardiovas-
cular disease within 5 years of toenail collection. Table S3. Relative Risk
of Cardiovascular Disease, according to quartiles of toenail mercury,
among case participants and matched controls in the PREDIMED trial,
restricted to participants who were below the 90th percentile of toenail
selenium. Table S4. Relative Risk of Cardiovascular Disease, according
to quartiles of toenail mercury, among case participants and matched
controls in the PREDIMED trial, stratified by baseline median fish intake
(below/above the median). Table S5. Relative Risk of Cardiovascular Disease,
according to quartiles of toenail mercury, among case participants and
matched controls in the PREDIMED trial, restricted to participants who were at
very high risk of cardiovascular disease. Table S6. Relative Risk of Cardiovascu-
lar Disease, according to quartiles of toenail mercury, among case participants
and matched controls in the PREDIMED trial, stratified by baseline aspirin use
(yes/no). Table S7. Bias analysis (simulation study). Sensitivity analysis to assess
the degree of plausible bias due to residual confounding, assuming an
unknown binary confounder (n-3 PUFA consumption; dichotomized at
median) with different prevalence among exposed (highest quartile of
mercury) and unexposed (lowest quartile of mercury) controls and with
a relatively strong association (even after adjusting for the known and
measured confounders) with cardiovascular disease. This correction was
applied to our observed OR=0.66 for the highest versus lowest quartile
of mercury exposure. (DOC 153 kb)
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